Ruth Adams
Chief Tech/Sci/R&D Officer bij NUVALENT, INC.
Profiel
Ruth Adams is currently working as the Vice President-Clinical Operations at Nuvalent, Inc. Prior to this, she worked as the Head-Clinical Operation at Vigeo Therapeutics, Inc. Ms. Adams completed her undergraduate degree from The University of Southampton.
Actieve functies van Ruth Adams
Bedrijven | Functie | Begin |
---|---|---|
NUVALENT, INC. | Chief Tech/Sci/R&D Officer | 01-11-2020 |
Eerdere bekende functies van Ruth Adams
Bedrijven | Functie | Einde |
---|---|---|
Vigeo Therapeutics, Inc.
Vigeo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Ruth Adams
The University of Southampton | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
NUVALENT, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Vigeo Therapeutics, Inc.
Vigeo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA. | Health Technology |